免疫系统
生物
免疫疗法
免疫学
免疫原性
细胞毒性T细胞
癌症研究
遗传学
体外
作者
Koen Brummel,Marta Requesens,Nienke van Rooij,Hagma H. Workel,Florine A. Eggink,Annechien Plat,René Wardenaar,Diana C.J. Spierings,Floris Foijer,David N. Church,Joost Bart,Hans W. Nijman,Marco de Bruyn
标识
DOI:10.1158/2326-6066.cir-25-0083
摘要
Abstract Polymerase epsilon–mutant (POLE-mut) endometrial cancers are characterized by a near 100% disease-specific survival rate, even when treated with surgery alone. This survival, combined with the ultramutated genome and high level of neoantigens in these tumors, indicates a substantial degree of immune control in preventing disease spread and recurrence. Although these features are intriguing, the analysis of immune infiltration in POLE-mut endometrial cancers has predominantly been confined to IHC studies. In this study, we used single-cell RNA and T-cell receptor sequencing to characterize the immune landscape of POLE-mut endometrial cancers. Moreover, we analyzed patient blood samples taken 2 to 8 years after curative treatment to assess the formation of long-term immune memory in circulation. We identified specialized tumor-infiltrating myeloid subsets at different stages of maturation, an array of lymphocytes ranging from immature to cytotoxic, and adaptive NK cells, as well as tumor-reactive exhausted and effector T cells, all contributing to a highly inflammatory antitumor response. Our analysis of blood samples taken years after curative treatment uncovered the presence of tumor-reactive T-cell clones that matched the primary tumor. This indicates the formation of systemic long-term memory immune responses in POLE-mut endometrial cancer survivors. Our study highlights the distinctive immunogenicity of POLE-mut endometrial cancer and identifies key features associated with persistent antitumor immunity that may contribute to prolonged, relapse-free survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI